Sign In
Last checked at 
20 Apr 2026 11:54
Bioventix plc
("Bioventix" or "the Company")
Share Options Awarded
Bioventix plc (BVXP), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, announces the award on 17 April 2026 of share options over ordinary shares in the Company (the "Options") under the Company's Share Option Plan in 2020 to the following directors, as follows:
Director | Position | Number of Options | Exercise Price | Total Number of Options held following this award |
Peter Harrison | CEO | 32,811 | £17.75 | 52,622 |
Bruce Hiscock | CFO | 9,967 | £17.75 | 14,394 |
The Options vest between 3 and 10 years from grant and will become exercisable once the Company recognises revenue of greater than £1.0 million, as evidenced by audited financial statements prepared in accordance with UK GAAP, from a commercial diagnostic partner relating to its neurological blood test using the Company's sheep monoclonal antibody. The Options are subject to clawback and malus provisions.
The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation ("MAR") EU no.596/2014. Upon the publication of this announcement via Regulatory Information Service ("RIS"), this inside information is now considered to be in the public domain.
For further information please contact:
Bioventix plc Peter Harrison |
Chief Executive Officer | Tel: 01252 728 001 |
Cavendish Geoff Nash / Elysia Bough Nigel Birks / Harriet Ward |
Corporate Finance ECM | Tel: 020 7220 0500 |
About Bioventix plc:
Bioventix (www.bioventix.com) specialises in the development and commercial supply of high-affinity monoclonal antibodies with a primary focus on their application in clinical diagnostics, such as in automated immunoassays used in blood testing. The antibodies created at Bioventix are generated in sheep and are of particular benefit where the target is present at low concentration and where conventional monoclonal or polyclonal antibodies have failed to produce a suitable reagent. Bioventix currently offers a portfolio of antibodies to customers for both commercial use and R&D purposes, for the diagnosis or monitoring of a broad range of conditions, including heart disease, cancer, fertility, thyroid function and drug abuse. Bioventix currently supplies antibody products and services to the majority of multinational clinical diagnostics companies. Bioventix is based in Farnham, UK and its shares are traded on AIM under the symbol BVXP.
The information below (set out in accordance with the requirements of UK Market Abuse Regulation) provides further detail:
1 | Details of the person discharging managerial responsibilities/person closely associated | ||||
a) | Name | a) Peter Harrison b) Bruce Hiscock | |||
2 | Reason for the notification | ||||
a) | Position/status | a) CEO b) CFO | |||
b) | Initial notification /Amendment | Initial Notification | |||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | Bioventix plc | |||
b) | LEI |
| |||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||
a) | Description of the financial instrument, type of instrument Identification code | Ordinary Shares of 5 pence each
GB00B4QVDF07 | |||
b) | Nature of the transaction | Issue of Options
| |||
c) | Price(s) and volume(s) | Exercise Price(s) | Volume(s) | ||
£17.75 £17.75 | 32,811 9,967 | ||||
d) | Aggregated information - Aggregated volume - Price |
42,778 £17.75
| |||
e) | Date of the transaction | 17 April 2026 | |||
f) | Place of the transaction | Outside a trading venue | |||
g) | Additional Information | N/A | |||
Follow the stocks
